Candriam SCA’s Audentes Therapeutics, Inc BOLD Stock Holding History

Candriam SCA’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-75,107	Closed	-$4.49M	–	809
2019 Q4	$4.49M	Sell	75,107 -225,693	-75%	-$8.47M	0.05%	393
2019 Q3	$8.45M	Hold	300,800	–	–	0.11%	213
2019 Q2	$11.3M	Hold	300,800	–	–	0.14%	168
2019 Q1	$11.7M	Hold	300,800	–	–	0.15%	159
2018 Q4	$6.41M	Buy	300,800 +62,000	+26%	+$1.6M	0.1%	239
2018 Q3	$9.45M	Buy	238,800 +169,300	+244%	+$6.31M	0.13%	199
2018 Q2	$2.66M	Buy	69,500 +11,500	+20%	+$426K	0.04%	423
2018 Q1	$1.74M	Buy	+58,000	New	+$1.96M	0.03%	505

Candriam SCA's BOLD Position: Q1 2020 in Review

Candriam SCA sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 75,107 shares — an estimated $4.49M sold.

Candriam SCA first reported a position in BOLD in Q1 2018 and held it in 8 quarters. The position peaked at $11.7M in Q1 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Candriam SCA reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Candriam SCA sold 75,107 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $4.49M.
Candriam SCA first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 8 quarters.
Candriam SCA's Audentes Therapeutics, Inc position peaked at $11.7M in Q1 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Candriam SCA's 13F filing for Q1 2020, filed 26 May 2020.